Aurobindo Pharma Limited (NSE: AUROPHARMA) announced today that it has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Beclomethasone Dipropionate HFA Inhalation Aerosol, 40 mcg and 80 mcg, a generic equivalent of QVAR® Inhalation Aerosol 40 mcg and 80 mcg, marketed by Teva Branded Pharmaceutical Products R&D LLC. This marks Aurobindo’s first metered-dose inhaler (MDI) product, signifying a significant milestone in the company’s expansion into complex respiratory therapies and strengthening its capabilities in the inhalation segment.

Manufacturing and Market Potential

The product will be manufactured at Aurobindo Pharma’s Raleigh facility in North Carolina, owned by its wholly-owned step-down subsidiary Aurolife Pharma LLC. The US market for the approved product and newer versions of the reference product, QVAR® Redi Haler, was estimated at US$301 million for the twelve months ended July 2026, according to IQVIA.

Therapeutic Benefits

Beclomethasone Dipropionate HFA Inhalation Aerosol is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. Indicated for asthma patients who require systemic corticosteroid administration, where adding Beclomethasone Dipropionate HFA Inhalation Aerosol may reduce or eliminate the need for the systemic corticosteroids.

Building on our leadership in Generics, we are now expanding into complex inhalation therapies to create the next wave of differentiated growth in the US market, stated Aurobindo Pharma Limited.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Aurobindo Pharma Limited

Aurobindo Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Aurobindo rises 14.1% over three months, with buying pressure holding steady. Revenue grows at 10.7% and profits at 22.1% CAGR. The market consistently rewards this kind of compounding. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock trades at 94% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Both the business and the stock move in the right direction. Revenue grows at 10.7%, profits at 22.1%, and the PEG sits at 1.19 — below its growth rate. That combination is rare. Check Fundamentals of Aurobindo Pharma Limited.

Aurobindo Pharma Limited (NSE: AUROPHARMA) is pleased to announce that Lannett Company LLC, a wholly-owned subsidiary, has launched the generic equivalent of Advair Diskus® (fluticasone propionate and salmeterol inhalation powder), a product of GSK plc, in the US market. This marks the first product from Aurobindo’s inhalation pipeline to be commercialized in the US, reflecting the company’s ongoing focus on expanding its portfolio of complex and differentiated inhalation products.

Advair Diskus® for Asthma and COPD

Advair Diskus® in combination therapy is indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD). This launch is a significant milestone for Aurobindo Pharma as it continues to build its robust portfolio in the respiratory therapeutic area.

Global Pharmaceutical Leader

Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients globally in over 150 countries. With 30+ manufacturing and packaging facilities approved by leading regulatory agencies, Aurobindo Pharma remains committed to delivering high-quality, affordable medications worldwide.

For more information, please visit www.aurobindo.com. For further inquiries, contact Investor Relations | Corporate Communications at Phone: +91 40 667 51211 | 66725000, Email: [email protected].

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Aurobindo Pharma Limited

Aurobindo Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Aurobindo gains 15.3% over three months and trades near its 52-week highs. Revenue grows at 10.7% and profits at 22.1% CAGR. The market consistently rewards this kind of compounding. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock trades at 94% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Both the business and the stock move in the right direction. Revenue grows at 10.7%, profits at 22.1%, and the PEG sits at 1.15 — below its growth rate. That combination is rare. Check Fundamentals of Aurobindo Pharma Limited.

Aurobindo Pharma Limited (AUROPHARMA) has unveiled its Q1FY27 earnings, showcasing a robust performance across all business areas. The company reported a revenue of ₹9,150 Cr, marking a 16.3% year-on-year growth. Net profit for the quarter stood at ₹1,032 Cr, reflecting a 25.2% increase compared to the same period last year.

Key Financial Highlights

The strong financial performance was driven by significant gains in the U.S. base business, which continued to expand due to volume growth and new product launches. Aurobindo Pharma Limited’s operating EBITDA stood at ₹1,924 Cr, with a margin of 21.0%. The company also generated free cash flow of US$ 98 Mn during the quarter, maintaining a strong net cash position of approximately US$ 42 million as of June 30, 2026.

Business Segment Performance

The U.S. revenue accounted for 41.2% of the consolidated revenue, growing by 5% sequentially, excluding the impact of Revlimid. The company launched 10 new products and received final approvals for another 10 products during the quarter. Europe and Growth Markets continued their momentum with respective year-on-year growth of 11% and 25%. API revenues increased by 14.6% year-on-year, although there was some seasonal softness in the antibiotics portfolio.

Looking Ahead

Aurobindo Pharma Limited remains optimistic about its strategic initiatives and future business developments. The company is committed to enhancing its capabilities and exploring new business opportunities to drive continued growth.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Aurobindo Pharma Limited

Aurobindo Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Aurobindo rises 9.1% over three months, with buying pressure holding steady. Revenue grows at 10.7% and profits at 22.1% CAGR. The market consistently rewards this kind of compounding. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock trades at 96% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Both the business and the stock move in the right direction. Revenue grows at 10.7%, profits at 22.1%, and the PEG sits at 1.21 — below its growth rate. That combination is rare. Check Fundamentals of Aurobindo Pharma Limited.